I completed my Doctor of Medicine (MD) in 2016 and worked as a cardiologist in China. My research work involved characterising metabolic remodelling of the heart in atrial fibrillation and the role of β3-adrenoceptor in the development of atrial fibrillation.
From 2019 to early 2024, I undertook my PhD with Professor Mark Febbraio at the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, where I focused on the therapeutic properties of the designer cytokine IC7Fc in metabolic diseases, including obesity, diabetes and metabolic dysfunction-associated steatohepatitis.
From May 2024, I undertook my postdoctoral research with Dr. Kim Loh at SVI. I am interested in the physiological and pathological properties of Salt-Inducible Kinase 3 in energy homeostasis and metabolic diseases.
Key Achievements
2020-2024 Monash International Graduate Research Scholarship
2013 Fund of National Student’s Platform for Innovation and Entrepreneurship Training Program
Diabetes & Metabolic Disease
We aim to identify and develop novel therapeutic target for diabetes, obesity and cardiovascular disease.
Lab head: Dr Kim LohSelected publications
Zhao JJ, Turpin-Nolan SM, Febbraio M. IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases. Cytokine. 2021; 144: p. 155549. doi: 10.1016/j.cyto.2021.155549
Dong JM, Zhao JJ, Zhang MM, Liu GZ, Wang XB, Liu YX, Yang N, Liu YW, Zhao GQ, Sun JY, Tian JP, Cheng CP, Wei L, Li Y, Li WM. β3-adrenoceptor impairs mitochondrial biogenesis and energy metabolism during rapid atrial pacing- induced atrial fibrillation. Journal of cardiovascular pharmacology and therapeutics. 2016; 21:114-126. doi: 10.1177/1074248415590440
Liu GZ, Hou TT, Yuan Y, Hang PZ, Zhao JJ, Sun L, Zhao GQ, Zhao J, Dong JM, Wang XB, Shi H, Liu YW, Zhou JH, Dong ZX, Liu Y, Zhan CC, Li Y, Li WM. Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through ppar-alpha/sirtuin 1/pgc-1alpha pathway. British journal of pharmacology. 2016; 173:1095-1109. doi: 10.1111/bph.13438